Related Experiment Video

Updated: Jul 3, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Role of gemifloxacin in community-acquired pneumonia

Glenn S Tillotson1

  • 1glenntillotson@cox.net

Expert Review of Anti-Infective Therapy
|July 30, 2008
PubMed

Insights

Community-acquired pneumonia (CAP) treatment is evolving. A 5-day course of gemifloxacin offers a safe, effective, and cost-efficient alternative for bacterial pneumonia, addressing rising antibiotic resistance.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Respiratory Medicine

Background:

  • Community-acquired pneumonia (CAP) is a significant cause of bacterial infection mortality.
  • Most CAP cases are treated in outpatient settings, often with prolonged oral antibiotic courses.
  • Increasing antibiotic resistance, particularly in Streptococcus pneumoniae, complicates CAP management.

Purpose of the Study:

  • To evaluate the efficacy and safety of gemifloxacin for treating CAP.
  • To assess gemifloxacin as a cost-effective alternative to traditional antibiotic regimens.
  • To address the challenge of emerging resistant respiratory pathogens in CAP.

Main Methods:

  • Clinical evaluation of gemifloxacin's effectiveness and tolerability.
  • Comparison of a 5-day gemifloxacin regimen with standard 10-day or longer oral antibiotic therapies.
  • Assessment of cost-effectiveness and safety profile.

Main Results:

  • Gemifloxacin demonstrated high efficacy and good tolerability in CAP patients.
  • A 5-day once-daily regimen was found to be effective.
  • Gemifloxacin covers key CAP pathogens, including resistant Streptococcus pneumoniae and atypical pathogens.

Conclusions:

  • A 5-7 day course of gemifloxacin is a cost-effective and safe alternative for CAP treatment.
  • Gemifloxacin provides an effective option against common and resistant CAP pathogens.
  • This regimen offers a shorter, well-tolerated treatment for community-acquired pneumonia.

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...